November 2023 in “Bioorganic Chemistry” Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.
July 2024 in “Reactions Weekly”
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Bicalutamide may be a promising alternative treatment for female pattern hair loss.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
1 citations
,
August 2024 in “Indian Dermatology Online Journal” Bicalutamide may effectively treat female pattern hair loss with minimal side effects.
41 citations
,
February 2021 in “Cureus” Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
16 citations
,
March 2020 in “Journal of The American Academy of Dermatology” Oral bicalutamide is safe and effective for female hair loss.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
1 citations
,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
August 2025 in “JAAD International” Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.
8 citations
,
October 2019 in “Dermatologic Therapy” Bicalutamide improves hair density in women safely.
May 2025 in “Journal of the American Academy of Dermatology” Bicalutamide shows promise for treating female hair loss.
December 2025 in “Actas Dermo-Sifiliográficas” Bicalutamide may improve hair growth in postmenopausal women with mild side effects.
5 citations
,
July 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.
19 citations
,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
17 citations
,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
4 citations
,
September 2024 in “BMC Cancer” Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
January 2023 in “International Journal of Trichology” Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.